Table 1.
Select patient and tumor characteristics.
| Median | Range | ||
|---|---|---|---|
| Age at radiation therapy (years) | 56 | 40–75 | |
| n (percent) | |||
| Race | |||
| White | 10 (38.5%) | ||
| Black | 9 (34.6%) | ||
| Other | 7 (26.9%) | ||
| Cancer location | |||
| Right breast | 14 (53.8%) | ||
| Left breast | 12 (46.2%) | ||
| Type of cancer | |||
| Ductal Carcinoma In Situ (DCIS) | 6 (23.1%) | ||
| Invasive Ductal Carcinoma (IDC) | 18 (69.2%) | ||
| Mucinous Carcinoma of the Breast | 1 (3.8%) | ||
| Invasive Lobular Carcinoma (ILC) | 1 (3.8%) | ||
| Tumor stage | |||
| Tis | 6 (23.1%) | ||
| T1 | 18 (69.2%) | ||
| T2 | 2 (7.7%) | ||
| Nodal stage | |||
| N0 | 25 (96.2%) | ||
| N1 | 1 (3.8%) | ||
| Stage grouping | |||
| 0 | 6 (23.1%) | ||
| I | 17 (65.4%) | ||
| II | 3 (11.5%) | ||
| Tumor grade | |||
| I | 9 (34.6%) | ||
| II | 13 (50.0%) | ||
| III | 4 (15.4%) | ||
| Estrogen receptor (ER) status | |||
| Positive | 24 (92.3%) | ||
| Negative | 2 (7.7%) | ||
| Progesterone receptor (PR) status | |||
| Positive | 18 (69.2%) | ||
| Negative | 8 (30.8%) | ||
| Human epidermal growth factor receptor (HER2) status a | |||
| Positive | 4 (16.7%) | ||
| Negative | 20 (83.3%) | ||
a
Not available for two patients.